Document 0039
 DOCN  M95A0039
 TI    [Anemia in AIDS: the problem to avoid. Human recombinant erythropoietin
       in the treatment of HIV positive patients]
 DT    9510
 AU    Karwacki M; Ochocka M; Kubiak W; Klinika Hematologii i Chorob
       Rozrostowych Dzieci AM w Warszawie.
 SO    Przegl Epidemiol. 1994;48(4):441-7. Unique Identifier : AIDSLINE
       MED/95320321
 AB    The most common hematological abnormality associated with HIV infection
       is anaemia. The aetiology is multifactorial and may include the HIV
       virus itself; the anaemia of chronic diseases (ACD); infection with
       other viruses, mycobacteria and fungi; medications, especially
       zidovudine; and even B12 deficiency. Erythropoietin insufficiency is
       present in all anaemic AIDS patients, probably as a result of the
       mechanism of ACD. The studies, performed in patients with PGL, ARC and
       AIDS stages of disease demonstrate that rHuEPO is safe, and in dose of
       100-200 U/kg b.w. three times a week can alleviate the anemia in AIDS
       patients taking AZT whose baseline EPO levels are less than 500 mU/ml.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS/DRUG THERAPY
       Anemia/*DRUG THERAPY/*ETIOLOGY  Chronic Disease  English Abstract
       Erythropoietin/*DEFICIENCY/METABOLISM/*THERAPEUTIC USE  Human
       Zidovudine/PHARMACOLOGY/THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).